Price Alert

Aerie Pharmaceuticals Inc... (AERI)

NASDAQ: AERI · Real-Time Price · USD

15.25

0.00 (0.00%)

At close: Nov 18, 2022, 10:00 PM

Aerie Pharmaceuticals Statistics

Share Statistics

Aerie Pharmaceuticals has 0 shares outstanding. The number of shares has increased by 3.69% in one year.

Shares Outstanding	n/a
Shares Change (YoY)	3.69%
Shares Change (QoQ)	2.67%
Owned by Institutions (%)	n/a
Shares Floating	43.85M
Failed to Deliver (FTD) Shares	n/a
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 1.4M, so 0% of the outstanding shares have been sold short.

Short Interest	1.4M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.39

Valuation Ratios

The PE ratio is -4.35 and the forward PE ratio is null. Aerie Pharmaceuticals's PEG ratio is 0.07.

PE Ratio	-4.35
Forward PE	n/a
PS Ratio	1.68
Forward PS	n/a
PB Ratio	-18.77
P/FCF Ratio	-3.18
PEG Ratio	0.07

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Aerie Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.85, with a Debt / Equity ratio of -15.04.

Current Ratio	2.85
Quick Ratio	2.52
Debt / Equity	-15.04
Debt / EBITDA	-33.36
Debt / FCF	-2.54
Interest Coverage	-1.57

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$516.31K
Profits Per Employee	$-198.96K
Employee Count	376
Asset Turnover	0.45
Inventory Turnover	0.66

Taxes

Income Tax	593K
Effective Tax Rate	-0.8%

Stock Price Statistics

The stock price has increased by 0% in the last 52 weeks. The beta is -0.06, so Aerie Pharmaceuticals's price volatility has been lower than the market average.

Beta	-0.06
52-Week Price Change	n/a
50-Day Moving Average	15.19
200-Day Moving Average	10.11
Relative Strength Index (RSI)	68.34
Average Volume (20 Days)	786,842

Income Statement

In the last 12 months, Aerie Pharmaceuticals had revenue of 194.13M and earned -74.81M in profits. Earnings per share was -1.61.

Revenue	194.13M
Gross Profit	167.29M
Operating Income	-45.31M
Net Income	-74.81M
EBITDA	-7.81M
EBIT	-44.27M
Earnings Per Share (EPS)	-1.61

Full Income Statement

Balance Sheet

The company has 37.19M in cash and 260.64M in debt, giving a net cash position of -223.46M.

Cash & Cash Equivalents	37.19M
Total Debt	260.64M
Net Cash	-223.46M
Retained Earnings	-1.15B
Total Assets	n/a
Working Capital	n/a

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -99.15M and capital expenditures -3.29M, giving a free cash flow of -102.44M.

Operating Cash Flow	-99.15M
Capital Expenditures	-3.29M
Free Cash Flow	-102.44M
FCF Per Share	-2.21

Full Cash Flow Statement

Margins

Gross margin is 86.17%, with operating and profit margins of -23.34% and -38.54%.

Gross Margin	86.17%
Operating Margin	-23.34%
Pretax Margin	-38.23%
Profit Margin	-38.54%
EBITDA Margin	-4.02%
EBIT Margin	-23.34%
FCF Margin	-52.77%

Dividends & Yields

AERI does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for AERI.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a